Tobacco smoking cessation management: Integrating varenicline in current practice

Vascular Health and Risk Management

Volumn 4, Issue 4, 2008, Pages 837-845

  Galanti, Laurence M ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Bupropion; Nicotine replacement therapy (NRT); Nicotinic substitution; Tobacco smoking cessation; Varenciline

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; EPIDEMIOLOGICAL DATA; EVENING DOSAGE; HEALTH HAZARD; HICCUP; HUMAN; INSOMNIA; JAW DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORBIDITY; MORNING DOSAGE; MORTALITY; MOTIVATION; MOUTH DISEASE; MOUTH PAIN; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; OPTIMAL DRUG DOSE; POLICY; PRIMARY MEDICAL CARE; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEIZURE; SKIN MANIFESTATION; SMOKING CESSATION; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT DURATION; XEROSTOMIA;

BEHAVIOR THERAPY; BENZAZEPINES; BUPROPION; DRUG PARTIAL AGONISM; HEALTH POLICY; HUMANS; NICOTINIC AGONISTS; PUBLIC POLICY; QUINOXALINES; RECEPTORS, NICOTINIC; RECURRENCE; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 52249093734     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. American Heart Association. 2008. Cigarette smoking and cardiovascular diseases [online]. Accessed 12 February 2008. URL: http://www.americanheart.org/downloadable/heart.
2. Benowitz NL. 1996. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev, 18:188-204.
3. Benowitz NL, Zevin S, Jacob P. 1997. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol, 43:259-67.
4. Cahill K, Stead LF, Lancaster T. 2007. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 1:CD0006103.
5. Centers for Disease Control and Prevention. 2005. Annual smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 1997-2001. MWR Morb Mortal Wkly Rep, 54:625-8.
6. Centers for Disease Control and Prevention. 2006. Cigarette smoking among adults. United States 2006. MMWR Morb Mortal Wkly Rep, 56:1157-61.
7. Coe JW, Brooks PR, Vetelino MG, et al. 2005. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem, 48:3474-7.
8. Coleman T. 2004. ABC of smoking cessation. Use of simple advice and behavioural support. BMJ, 328:397-9.
9. Corelli RL, Hudman SK. 2006. Pharmacologic interventions for smoking cessation. Crit Care Nurs Clin N Am, 18:39-51.
10. Dempsey DA, Benowitz NL. 2001. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf, 24:277-322.
11. Faessel HM, Gibbs MA, Clark DJ, et al. 2006a. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol, 46:1439-48.
12. Faessel HM, Smith BJ, Gibbs MA, et al. 2006b. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and non-smokers. J Clin Pharmacol, 46:991-8.
13. Fichtenberg CM, Glantz SA. 2002. Effect of smoke-free workplaces on smoking behaviour systematic review. BMJ, 325:188-91.
14. Fiore MC, Bailey WC, Cohen SJ, et al. 2000. Treating tobacco use and dependence. 2000. Clinical practice guideline. Rockville (MD): US Department of Health and Human Services, Public Health Service.
15. Frishman WH, Mitta W, Kupersmith A, et al. 2006. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev, 14:57-73.
16. Gonzales D, Rennard SI, Nides M, et al. 2006. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA, 296:47-55.
17. Gourlay SG, Benowitz NL, Forbes A, et al. 1997. Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment. Eur J Clin Pharmacol, 51:407-14.
18. Greenland P, Knoll MD, Stamler J, et al. 2003. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA, 290:891-7.
19. Gries JM, Benowitz N, Verotta D. 1998. Importance of chronopharmacokinetics in design and evaluation, of transdermal drug delivery systems. J Pharmacol Exp Ther, 28:457-63.
20. Health Canada. Canada Tobacco Use Monitoring Survey (CTUMS). 2007. Ottawa: Health Canada; 2007 [online]. Access 12 February 2008. URL: http://www.hc-sc.gc.ca/hl-vs/tobac-tabac/research-recherche/stat/ ctums-esutc_2006_e.html.
21. Hays JT, Hurt RD, Rigotti NA, et al. 2001. Sustained-released bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med, 135:423-33.
22. Hu T, Sung H, Keeler T. 1995. Reducing cigarette consumption in California: tobacco taxes vs an anti-smoking media campaign. Am J Public Health, 89:1218-22.
23. Hughes JR, Stead LF, Lancaster T. 2007. Antidepressants for smoking cessation. Cochrane Database Syst Rev, 1: CD00031.
24. Hurt RD, Sachs DPL, Glover ED, et al. 1997. A comparison of sustained release bupropion and placebo for smoking cessation. N Engl J Med, 337:1195-202.
25. Hyland A, Borland R, Li Q, et al. 2006. Individual-level predictors of cessation behaviors among participants in the international tobacco control (ITC) four country survey. Tob Control, 15(Suppl 3):83-94.
26. Jorenby D. 2002. Clinical efficacy of bupropion in the management of smoking cessation. Drugs, 62(Suppl 2):25-35.
27. Jorenby DE, Hays JT, Rigotti NA, et al. 2006. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA, 296:56-63.
28. Joseph AM, Norman SM, Ferry LH, et al. 1996. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med, 335:1792-8.
29. Lagrue G, Philippon C, Lafhoune N, et al. 1994. Le dosage de la cotinine urinaire: un guide pour l'adaptation posologique du traitement de la dépendance tabagique par la nicotine. Sem Hôpitaux Paris, 70:387-90.
30. Lancaster T, Stead L, Silagy C, et al. 2000a. Effectiveness of interventions to help people stop smoking findings from the Cochrane library. BMJ, 321:355-8.
31. Lancaster T, Stead LF. 2000b. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev, 2:CD001292.
32. Larramendy C, Diviné C, Asnafi-Farhang S, et al. 2004. Usefulness of biological markers in evaluation of smoking. Pathologie Biologie, 52:164-72.
33. Le Foll, Aubin HJ, Lagrue G. 2002. Behavioral and cognitive therapy to beak the smoking habit. Review of the literature. Ann Med Interne (Paris), 153(3 Suppl):32-40.
34. Le Foll B, George TP. 2007. Treatment of tobacco dependence: integrating recent progress into practice. CMAJ, 177:1373-80.
35. McRobbie H, Hajek P. 2001. Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction, 96:1547-51.
36. Meine TJ, Patel MR, Washam JB, et al. 2005. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol, 95:976-8.
37. Mihalak KB, Carroll FI, Luetje CW. 2006. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol, 70:801-5.
38. Moolchan ET, Robinson MI, Ernst M, et al. 2005. Safety of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics, 115:e407-e414.
39. Nides M, Oncken C, Gonzales D, et al. 2006. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: result from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-Year follow-up. Arch Inter Med, 166:1547-50.
40. Nomikos GG, Damsma G, Wenkstern D, et al. 1989. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology, 2:273-9.
41. Obacb RS, Reed-Hagen AE, Krueger SS, et al. 2006. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor agonist, in vivo and in vitro. Drug Metab Dispos, 34:121-30.
42. Oncken C, Gonzales D, Nides M, et al. 2006. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Int Med, 166:1571-7.
43. Pfizer. 2008. Varenicline summary of product characteristics [online]. Accessed 12 February 2008. URL: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/champix/H-699-PI-en.pdf.
44. Pisinger C, Vestbo J, Borch-Johnsen K, et al. 2005. It is possible to help smokers in early motivational stages to quit. The Inter99 study. Prev Med, 40:278-84.
45. Shafey O, Dolwick S, Guindon GE, Eds. 2003. Tobacco control country profiles 2003. Atlanta: American Cancer Society, World Health Organization and International Union Against Cancer [online]. Accessed 12 February 2008. URL: http://www.who.int/tobacco/global_data/ country_profiles/Introduction.pdf.
46. Silagy C, Lancaster T, Stead L, et al. 2004. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 3:CD000146.
47. Slemmer JE, Martin BR, Damaj MI. 2000. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther, 295:321-7.
48. Stapleton JA, Watson L, Spirling LI, et al. 2008. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction, 103:146-54.
49. Stead LF, Perera R, Bullen C, et al. 2008. Nicotine replacement therapy for smoking cessation (Review). Cochrane Database Syst Rev, 1:CD000146.
50. Tonstad S, Tonnesen P, Hajek P, et al. 2006. Effect of maintenance therapy with varenicline on smoking cessation. A randomized controlled trial. JAMA, 296:64-71.
51. Vasan RS, Sullivan LM, Wilson PW, et al. 2005. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Inter Med, 142:393-402.
52. Weinstein ND. 1998. Accuracy of smokers' risk perceptions. Ann Behav Med, 20:135-40.
53. West R, McNeill A, Raw M. 2000. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax, 55:987-99.
54. Williams KE, Reeves KR, Billing CB, et al. 2007. A double-blind study evaluation the long-term safety of varenicline for smoking cessation. Curr Med Res Opin, 23:793-801.
55. World Health Organization (WHO). 2002. The world health report 2002 - reducing risks, promoting healthy life [online]. Accessed 12 February 2008. URL: http://www.who.int/whr/2002/en/index.html.
56. World Health Organization (WHO). 2007. The European tobacco control report 2007 [online]. Accessed 12 February 2008. URL: http://www.euro.who.int/Document/E89842.pdf
57. Yusuf S, Hawken S, Öunpuu S, et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 364:937-52.